

February 1, 2021

## **Q3FY21 Result Update**

☑ Change in Estimates | ☑ Target | ■ Reco

### **Change in Estimates**

				•		
	Cur	rent	Previous			
	FY22E	FY23E	FY22E	FY23E		
Rating	В	UY	В	UY		
Target Price	1,7	727	1,526			
Sales (Rs. m)	47,388	54,175	46,761	53,441		
% Chng.	1.3	1.4				
EBITDA (Rs. m)	8,164	9,344	7,710	8,536		
% Chng.	5.9	9.5				
EPS (Rs.)	70.6	82.2	65.7	72.6		
% Chng.	7.5	13.2				

### **Key Financials - Standalone**

Y/e Mar	FY20	FY21E	FY22E	FY23E
Sales (Rs. m)	35,658	41,643	47,388	54,175
EBITDA (Rs. m)	4,929	6,799	8,164	9,344
Margin (%)	13.8	16.3	17.2	17.2
PAT (Rs. m)	3,403	4,450	5,646	6,576
EPS (Rs.)	42.5	55.6	70.6	82.2
Gr. (%)	(4.3)	30.8	26.9	16.5
DPS (Rs.)	11.1	14.6	18.5	21.5
Yield (%)	0.7	1.0	1.2	1.4
RoE (%)	14.4	17.5	19.5	19.8
RoCE (%)	13.8	19.6	21.0	21.6
EV/Sales (x)	3.0	2.5	2.1	1.8
EV/EBITDA (x)	21.7	15.3	12.3	10.2
PE (x)	35.8	27.4	21.6	18.5
P/BV (x)	4.9	4.3	3.8	3.3

Key Data	PERS.BO   PSYS IN
52-W High / Low	Rs.1,700 / Rs.420
Sensex / Nifty	46,286 / 13,635
Market Cap	Rs.116bn/ \$ 1,597m
Shares Outstanding	76m
3M Avg. Daily Value	Rs 452 77m

### **Shareholding Pattern (%)**

Promoter's	34.05
Foreign	18.71
Domestic Institution	29.52
Public & Others	17.72
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	2.3	71.7	117.5
Relative	5.2	41.2	93.6

### **Aniket Pande**

aniketpande@plindia.com | 91-22-66322300

### Aditi Patil

aditipatil@plindia.com |

# **Persistent Systems (PSYS IN)**

Rating: BUY | CMP: Rs1,524 | TP: Rs1,727

## Margin expansion on cards...

### **Quick Pointers:**

- Persistent's reported one of the healthiest TCV of 302mn and out of this the net new TCV is 175.5 mn. Total ACV of 256 mn and net new ACV of 140.1 mn indicates strong growth momentum for FY22.
- EBIT Margin of 12.7%, improvement of +60 bps QoQ & +394 bps YoY despite
  of wage hike rollout in Nov 2020. There is further scope for expansion in
  margins led by automation and revenue acceleration

Persistent reported strong beat of 290bps in revenue growth with revenue at \$146.15 mn, +7.4% QoQ USD. Growth was led by sustained strong performances in Services revenues (+5% QoQ USD) and strong recovery in IP led revenues (+20.0% QoQ USD) supported by seasonally strong quarter for IP business. Revenue growth momentum will continue supported by one of the heathiest TCV of 302\$ mn and ACV of 256\$mn. EBIT margin came at 12.7%, +60 bps QoQ and management guided that there are cost optimization levers and revenue growth will provide scope for margins to increase further. We expect stable margin performance in FY22/23E EBIT margin at 12%.

Large deal pipeline is healthy and we expect deal win traction to continue. Persistent is doubling down its efforts to expand in Europe, deepen its presence in alliance led business, and winning large deals across Healthcare and BFSI verticals apart from traditional strong foothold in Tech Cos & emerging vertical business. We believe acceleration of revenue momentum, sustainability of margins along with strong deal wins will lead to further rerating. We continue to value Persistent on 21X FY23 earnings to arrive at changed TP of INR 1727 (earlier: 1526). Persistent is currently trading at 21.6x/18.5x on FY22/23 earnings of INR 70/82. Maintain Buy.

- Strong beat in revenue growth: Persistent reported strong beat of 290bps in revenue growth. Reported revenues were \$146.15 mn, +7.4% QoQ USD (Ple & Cons: 4.5% QoQ USD). Growth was led by sustained strong performances in Services revenues (+5% QoQ USD) and strong recovery in IP led revenues (+20.0% QoQ USD). (3Q is seasonally strong quarter for this IP business). Growth in Services was volume led (offshore: +11.5% QoQ) with further decline in pricing (Onsite: -1.2% QoQ, Offshore: -2.3% QoQ). Capiot business contributed \$1mn to Services revenue.
- Strong growth from non-top 10 clients: Revenue growth was led by strong growth from non-top 10 clients 15% QoQ USD whereas top 10 client revenues remained muted (-0.1% QoQ USD). Top client grew at +2.4% QoQ USD on top of high growth of +13.8% QoQ USD in 2Q while there was fall in top 2-5 client revenues -6.6% QoQ USD.
- Tech cos & emerging verticals (51% of revs) grew at strong rate of 13.2% QoQ, followed by Healthcare & Life Sciences +6.3% QoQ USD. In Healthcare vertical they see strong traction in CX on provider side and product development, AI/ML related work on medical device side. Tec cos vertical has



Persistent has won a large multi-year deal with one of the top 5 banks globally. They are seeing strong traction in compliance, core modernization led by cloud & digital banking space in this sector

Persistent's reported one of the healthiest TCV (including small to large, new to existing deals) of 302mn and out of this the net new TCV is 175.5 mn. Total ACV of 256 mn and net new ACV of 140.1 mn indicates strong growth momentum for FY22

Recognised by Zinnov as top 3 in consumer software, enterprise software and platform engineering in ER&D space

been traditionally strong hold of Persistent and continued this journey by large deals wins

- BFSI declined by 0.7% QoQ USD. This decline can be attributed to cost control by couple of large customer in terms of furloughs and some intermittent ramp downs. However, this will normalize and growth will return to traditional levels in BFSI. They have also won a large multi-year deal with one of the top 5 banks globally. They are seeing strong traction in compliance, core modernization led by cloud & digital banking space in this sector.
- Strong Deal pipeline: Persistent's reported one of the healthiest TCV (including small to large, new to existing deals) of 302mn and out of this the net new TCV is 175.5 mn. The tenure of the deals ranges from shorter term deals of 1-1.5 years to larger ones of 5-7 years. Total ACV of 256 mn and net new ACV of 140.1 mn indicates strong growth momentum for FY22. Large deal wins were spread across verticals 4 in Tech Cos & Emerging Verticals, 4 in BFSI and 3 in Healthcare & Life Sciences vertical.
- Double down on Europe (8.8% of revs): Persistent has 80% of revenues coming from US and now they are expanding their reach in Europe with aim to get 15-18% of revenues from this region over next few years. They have done couple of acquisitions in Europe in last few year and are adding to the leadership team over there. They are also on lookout for acquisitions at the intersection of European presence and capabilities cloud, security, data analytics.
- Good traction in alliance business: Management is confident that alliance business will return to strong growth in coming few quarters. Persistent expanded their relationship with largest customer IBM into IBM cloud Telco, & Cloud pack and also across verticals such as healthcare. Persistent has also become advanced tier partner with RedHat. They have also won large deals in alliance business which are expected to ramp up in 1QFY22. We believe that alliance business will have healthy growth trajectory ahead.
- Strong sustainable EBIT Margin: Persistent posted strong EBIT Margin of 12.7% (Ple: 12.8%) up 60 bps QoQ & +394 bps YoY despite of wage hike rollout in Nov 2020 because of i) high utilization blended utilization remained at elevated levels of 81% in Q3 vs 81.2% in Q2 ii) higher offshoring increased by 117 bps to 87.8% in 3Q and iii) benefit of operating leverage led by strong revenue growth. Other operating expenses reduced by 100bps led by cost optimization initiatives. In Q2, impact of pay hike was only in two months whereas in Q3 full impact of pay hike will be seen. However, management indicated that they have sufficient levers in terms of automation and revenue acceleration to sustain and improve margins.
- Strong lateral headcount addition: Persistent added 1618 FTEs in 3Q, highest ever in a quarter. Major proportion (70%) of them are lateral hires, hired to meet the demand for orders booked in the past 2-3 quarters. They have implemented hybrid work model with employees coming partially to office. LTM attrition rate further decreased by 30 bps QoQ to 10.3%. PAT was at 1209 Mn INR up 18.5% QoQ.




Strong cash collections: Collections have been strong in this quarter at 150.4\$ mn leading to further reduction in DSO by 6 days QoQ to 57 days (vs 63 in 2Q21 and 68 in 3Q20). Board has declared an interim dividend of INR 14/share. They have completed the acquisition of Capiot and onboarding of 200 Capiot employees skilled in MuleSoft, TIBCO and RedHat platforms. Persistent is actively looking for capability led acquisitions in cloud, security and data analytics space.

**Exhibit 1: Q3FY21 Result Summary** 

Particulars (Rs mn)	3QFY21	2QFY21	QoQ gr.	3QFY20	YoY gr.	Ple	Var (ACT. Vs. Est)
Sales (USD mn)	146	136	7.4%	129	12.9%	142	2.8%
Sales	10,754	10,077	6.7%	9,227	16.5%	10,492	2.5%
EBITDA	1,825	1,658	10.1%	1,234	47.8%	1,805	1.1%
EBITDA Margins	17.0%	16.4%	52bp	13.4%	359bp	17.2%	-23.2
EBIT	1,364	1,218	12.0%	806	69.2%	1,343	1.5%
EBIT Margins	12.7%	12.1%	60bp	8.7%	395bp	12.8%	-11.9
PAT	1,209	1,020	18.6%	879	37.5%	1,298	-6.9%
EPS (diluted)	15.1	13.3	13.3%	11.0	37.5%	17.0	-11.0%


Source: Company, PL

Exhibit 2: USD revenue growth QoQ (%)




Source: Company, PL

Exhibit 3: USD revenue growth YoY (%)



Source: Company, PL

**Exhibit 4: IP revenues leading growth** 



Source: Company, PL



**Exhibit 5: Geography-wise revenues** 

USD in Mn	3QFY21	2QFY21	QoQ gr.	3QFY20	YoY gr.
America	118.5	112.8	5.1%	103.7	14.3%
Europe	12.9	10.3	24.3%	13.7	-6.3%
APAC	14.8	12.9	14.2%	12.0	22.6%
Total	146.2	136.1	7%	129.4	12.9%
-as a % of sales					
America	81.1%	82.9%	-180bp	80.1%	100bp
Europe	8.8%	7.6%	120bp	10.6%	-180bp
APAC	10.1%	9.5%	60bp	9.3%	80bp

Source: Company, PL

**Exhibit 6: Revenue by Industry classification** 

USD in Mn	3QFY21	2QFY21	QoQ gr.	3QFY20	YoY gr.
ISV	119.7	114.0	5%	50.5	137.1%
IP led	26.5	22.0	20%	27.4	-3.6%
Total	146.2	136.1	7%	77.9	87.6%
-as a % of sales					
ISV	81.9%	83.8%	-190bp	39.0%	4290bp
IP led	18.1%	16.2%	190bp	21.2%	-310bp

Source: Company, PL

## Exhibit 7: Revenue contribution by Geography (%)

Revenue by geography (%)	Q3FY18	Q4FY18	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21
America	84.4%	80.9%	79.7%	82.6%	83.7%	80.9%	82.5%	81.4%	80.1%	80.2%	80.4%	82.9%	81.1%
Europe	7.3%	8.2%	12.0%	7.5%	7.6%	7.9%	8.5%	9.9%	10.6%	8.8%	10.2%	7.6%	8.8%
APAC	8.3%	10.9%	8.3%	9.9%	8.7%	11.2%	9.0%	8.7%	9.3%	11.0%	9.4%	9.5%	10.1%

Source: Company, PL

### **Exhibit 8: Client Metrics**

Revenue by clients (%)	Q3FY18	Q4FY18	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21
Top Client	28.0%	21.7%	23.8%	25.7%	26.3%	20.2%	23.6%	23.7%	21.5%	19.2%	17.7%	19.4%	18.5%
Top 5 Clients	46.3%	40.9%	43.8%	43.3%	45.0%	40.0%	44.6%	44.3%	42.3%	41.5%	40.8%	41.6%	37.8%
Top 10 Clients	55.3%	49.9%	53.7%	52.4%	54.6%	50.2%	52.6%	53.4%	51.1%	49.9%	49.0%	50.5%	47.0%
Non Top 10 Clients	44.7%	50.1%	46.3%	47.6%	45.4%	49.8%	47.4%	46.6%	48.9%	50.1%	51.0%	49.5%	53.0%

Source: Company, PL

February 1, 2021



## **Exhibit 9: Other Operating Metrics**

Billing rates (USD/p.p.m)	Q3FY18	Q4FY18	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21
Rest of the world	16314	16662	16360	15787	16204	16846	16742	17155	16761	17276	17036	16993	16790
India	4220	4349	4333	4372	4392	4385	4427	4437	4420	4427	4308	4304	4204
Billed person months													
Rest of the World	2,413	2,391	2,348	2,221	2,232	2,206	2,179	2,271	2,430	2,425	2,595	2,647	2,651
India	11,922	11,728	11,857	12,097	12,402	12,674	12,962	13,138	13,865	14,550	14,866	16,033	17,879
TOTAL	14,335	14,119	14,205	14,318	14,634	14,880	15,141	15,409	16,295	16,975	17,461	18,680	20,530
Others													
DSO Days	66	66	68	63	61	63	65	64	68	65	69	63	57

Source: Company, PL



## **Financials**

ncome	Statement (	(Rsm)

Income Statement (Rs m) Y/e Mar	FY20	FY21E	FY22E	FY23E
Net Revenues	35,658	41,643	47,388	54,175
YoY gr. (%) Employee Cost	<i>5.9</i> 23,495	16.8 27,262	13.8	14.3
Gross Profit	12,164	14,381	30,451 16,937	34,802 19,374
Margin (%)	34.1	34.5	35.7	35.8
SG&A Expenses	34.7	34.0	30.7	33.0
Other Expenses	7,234	7,582	8,773	10,030
EBITDA	4,929	6,799	8,164	9,344
YoY gr. (%)	(15.1)	37.9	20.1	14.4
Margin (%)	13.8	16.3	17.2	17.2
Depreciation and Amortization	1,660	1,816	2,085	2,167
EBIT	3,270	4,984	6,079	7,177
Margin (%)	9.2	12.0	12.8	13.2
Net Interest	-	-	-	-
Other Income	1,254	1,035	1,500	1,650
Profit Before Tax	4,523	6,019	7,579	8,827
Margin (%)	12.7	14.5	16.0	16.3
Total Tax	1,121	1,569	1,933	2,251
Effective tax rate (%)	24.8	26.1	25.5	25.5
Profit after tax	3,403	4,450	5,646	6,576
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	3,403	4,450	5,646	6,576
YoY gr. (%)	(3.3)	30.8	26.9	16.5
Margin (%)	9.5	10.7	11.9	12.1
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	3,403	4,450	5,646	6,576
YoY gr. (%)	(3.3)	30.8	26.9	16.5
Margin (%)	9.5	10.7	11.9	12.1
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,403	4,450	5,646	6,576
Equity Shares O/s (m)	76	76	76	76
EPS (Rs)	42.5	55.6	70.6	82.2

Source: Company Data, PL Research

**Balance Sheet Abstract (Rs m)** 

<b>Balance Sheet Abstract (Rs</b>	m)			
Y/e Mar	FY20	FY21E	FY22E	FY23E
Non-Current Assets				
Gross Block	15,364	16,164	16,964	17,764
Tangibles	7,370	7,770	8,170	8,570
Intangibles	7,994	8,394	8,794	9,194
Acc: Dep / Amortization	11,705	13,520	15,606	17,773
Tangibles	5,145	5,781	6,511	7,269
Intangibles	6,559	7,739	9,095	10,503
Net fixed assets	3,660	2,644	1,359	(9)
Tangibles	2,225	1,989	1,659	1,301
Intangibles	1,435	655	(301)	(1,309)
Capital Work In Progress	870	870	870	870
Goodwill	89	89	89	89
Non-Current Investments	5,156	5,256	5,356	5,456
Net Deferred tax assets	960	960	960	960
Other Non-Current Assets	331	331	331	331
Current Assets				
Investments	5,164	5,164	5,164	5,164
Inventories	-	-	-	-
Trade receivables	5,922	6,845	7,790	8,906
Cash & Bank Balance	4,572	7,262	11,331	15,957
Other Current Assets	2,116	2,166	2,216	2,266
Total Assets	30,923	34,117	38,429	43,447
Equity				
Equity Share Capital	764	764	764	764
Other Equity	23,093	26,204	30,151	34,747
Total Networth	23,858	26,968	30,915	35,511
Non-Current Liabilities				
Long Term borrowings	46	46	46	46
Provisions	183	183	183	183
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	2,248	2,282	2,597	2,969
Other current liabilities	4,227	4,277	4,327	4,377
Total Equity & Liabilities	30,923	34,117	38,429	43,447

Source: Company Data, PL Research



Cash Flow (Rs m)				
Y/e Mar	FY20	FY21E	FY22E	FY23E
PBT	4,523	6,019	7,579	8,827
Add. Depreciation	1,660	1,816	2,085	2,167
Add. Interest	(545)	(645)	(660)	(750)
Less Financial Other Income	1,254	1,035	1,500	1,650
Add. Other	287	-	-	-
Op. profit before WC changes	5,925	7,190	9,004	10,244
Net Changes-WC	(1,369)	(1,437)	(1,163)	(1,338)
Direct tax	(1,328)	(1,569)	(1,933)	(2,251)
Net cash from Op. activities	3,228	4,184	5,909	6,655
Capital expenditures	(1,144)	(800)	(800)	(800)
Interest / Dividend Income	518	645	660	750
Others	515	-	-	-
Net Cash from Invt. activities	(111)	(155)	(140)	(50)
Issue of share cap. / premium	-	-	-	-
Debt changes	35	-	-	-
Dividend paid	(2,823)	(1,113)	(1,412)	(1,644)
Interest paid	(63)	-	-	-
Others	(154)	(227)	(288)	(335)
Net cash from Fin. activities	(3,006)	(1,339)	(1,700)	(1,979)
Net change in cash	111	2,690	4,069	4,626
Free Cash Flow	2,034	3,384	5,109	5,855

Source: Company Data, PL Research

### Quarterly Financials (Rs m)

Y/e Mar	Q4FY20	Q1FY21	Q2FY21	Q3FY21
Net Revenue	9,264	9,914	10,077	10,754
YoY gr. (%)	11.4	19.1	13.9	16.5
Raw Material Expenses	6,130	6,646	6,577	7,064
Gross Profit	3,134	3,267	3,501	3,690
Margin (%)	33.8	33.0	34.7	34.3
EBITDA	1,277	1,464	1,658	1,825
YoY gr. (%)	0.9	21.8	36.3	47.8
Margin (%)	13.8	14.8	16.4	17.0
Depreciation / Depletion	420	436	440	461
EBIT	857	1,029	1,218	1,364
Margin (%)	9.2	10.4	12.1	12.7
Net Interest	-	-	-	-
Other Income	274	192	157	286
Profit before Tax	1,130	1,220	1,375	1,650
Margin (%)	12.2	12.3	13.6	15.3
Total Tax	292	320	355	441
Effective tax rate (%)	25.9	26.2	25.8	26.7
Profit after Tax	838	900	1,020	1,209
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	838	900	1,020	1,209
YoY gr. (%)	(0.8)	9.1	18.5	37.5
Margin (%)	9.0	9.1	10.1	11.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	838	900	1,020	1,209
YoY gr. (%)	(0.8)	9.1	18.5	37.5
Margin (%)	9.0	9.1	10.1	11.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	838	900	1,020	1,209
Avg. Shares O/s (m)	80	80	76	80
EPS (Rs)	10.5	11.3	13.3	15.1

Source: Company Data, PL Research

<b>Key Financial Metrics</b>				
Y/e Mar	FY20	FY21E	FY22E	FY23E
Per Share(Rs)				
EPS	42.5	55.6	70.6	82.2
CEPS	66.2	82.0	101.2	114.4
BVPS	312.2	352.9	404.5	464.7
FCF	26.6	44.3	66.8	76.6
DPS	11.1	14.6	18.5	21.5
Return Ratio(%)				
RoCE	13.8	19.6	21.0	21.6
ROIC	17.4	25.3	31.3	37.0
RoE	14.4	17.5	19.5	19.8
Balance Sheet				
Net Debt : Equity (x)	(0.4)	(0.5)	(0.5)	(0.6)
Debtor (Days)	61	60	60	60
Valuation(x)				
PER	35.8	27.4	21.6	18.5
P/B	4.9	4.3	3.8	3.3
P/CEPS	66.2	82.0	101.2	114.4
EV/EBITDA	21.7	15.3	12.3	10.2
EV/Sales	3.0	2.5	2.1	1.8
Dividend Yield (%)	0.7	1.0	1.2	1.4

Source: Company Data, PL Research





### **Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Coforge	BUY	3,051	2,420
2	Cyient	BUY	681	508
3	HCL Technologies	BUY	1,160	990
4	Infosys	BUY	1,611	1,387
5	L&T Technology Services	BUY	3,057	2,658
6	Larsen & Toubro Infotech	BUY	4,364	4,091
7	Mindtree	BUY	1,940	1,664
8	Mphasis	BUY	1,719	1,599
9	Persistent Systems	BUY	1,526	1,498
10	Redington (India)	BUY	138	133
11	Sonata Software	BUY	437	393
12	Tata Consultancy Services	BUY	3,358	2,928
13	TeamLease Services	BUY	2,931	2,666
14	Tech Mahindra	BUY	1,099	978
15	Wipro	BUY	493	459
16	Zensar Technologies	BUY	257	243

## PL's Recommendation Nomenclature (Absolute Performance)

 Buy
 : > 15%

 Accumulate
 : 5% to 15%

 Hold
 : +5% to -5%

 Reduce
 : -5% to -15%

 Sell
 : < -15%</td>

Not Rated (NR) : No specific call on the stock
Under Review (UR) : Rating likely to change shortly



### **ANALYST CERTIFICATION**

### (Indian Clients)

We/l, Mr. Aniket Pande- MBA, Ms. Aditi Patil- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

### **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Aniket Pande- MBA, Ms. Aditi Patil- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

### Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com